Chemical Structure : Crizotinib hydrochloride
CAS No.: 1415560-69-8
Catalog No.: PC-45886Not For Human Use, Lab Use Only.
Crizotinib (PF-02341066;PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM.
Packing | Price | Stock | Quantity |
---|---|---|---|
50 mg | $80 | In stock | |
100 mg | $112 | In stock | |
200 mg | $192 | In stock | |
500 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Crizotinib (PF-02341066;PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM; displays >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB; also inhibits ALK (IC50=24 nM), potently inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50=5-20 nM); shows antitumor efficacy in tumor models at well-tolerated doses in vivo.
Lung Cancer
Approved
M.Wt | 486.7976 | |
Formula | C21H23Cl3FN5O | |
Appearance | Solid | |
Storage |
|
|
Solubility |
DMSO: ≥ 4.6 mg/mL |
|
Chemical Name/SMILES |
2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-, hydrochloride (1:1) |
1. Zou HY, et al. Cancer Res. 2007 May 1;67(9):4408-17.
2. Christensen JG, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.
3. Knowles LM, et al. Clin Cancer Res. 2009 Jun 1;15(11):3740-50.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright